Status:
UNKNOWN
Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Evaluate Bone Changes in Patients With PsA
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arth...
Detailed Description
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in individuals with psoriasis. It is estimated that 1% to 3% of the general population have psoriasis.1,2,3 In Europe the prev...
Eligibility Criteria
Inclusion
- Males/females with CASPAR criteria-positive PsA
- Active disease with more than three swollen and tender joints
- Must be aged ≥ 18 years at time of consent
- ≥ 3 erosions on MRI or HR PQCT
- Women of childbearing potential or men capable of fathering children must be using effective contraception during treatment with abatacept and up to 14 weeks after the last dose of abatacept treatment.
- Must understand and voluntarily sign an informed consent form including written consent for data protection ´- Must be able to adhere to the study visit schedule and other protocol requirements
Exclusion
- Previous exposure to abatacept
- CCP2 positivity
- Investigational study drug within 4 weeks (or 5 halflives (half live is 14,3 days), whichever is longer) prior to randomisation
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, SpA, Behcet disease, vasculitis or autoimmune hepatitis.
- Any malignancy in the last 5 years
- Chronic infection such as latent TB (TB not adequately treated according to guidelines) or hepatitis B or C infection
- Immunocompromised or HIV-positive patients
- Uncontrolled severe concomitant disease
- Patients who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG).
- Pregnant or lactating females
- Patients who possibly are dependent on the Principal Investigator or
Key Trial Info
Start Date :
June 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04106804
Start Date
June 6 2018
End Date
August 1 2022
Last Update
September 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Clinic Erlangen, Medical Department 3, Rheumatology & Immunology
Erlangen, Germany, 91054